Joan H Schiller

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi request reprint Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy
    Tien Hoang
    Department of Medicine, University of Wisconsin Medical School, Madison 53792, USA
    Expert Rev Anticancer Ther 2:393-401. 2002
  2. ncbi request reprint Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
  3. doi request reprint Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000)
    Joan H Schiller
    University of Texas Southwestern, Dallas, Texas 75390 8852, USA
    Cancer Invest 26:81-95. 2008
  4. doi request reprint Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study
    Joan H Schiller
    University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8852, USA
    J Clin Oncol 27:3836-41. 2009
  5. pmc Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea
    David E Gerber
    Division of Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    J Clin Oncol 31:1009-20. 2013
  6. ncbi request reprint Angiogenesis inhibitors in the treatment of lung cancer
    Sophie Sun
    Division of Hematology and Oncology, University of Texas Southwestern, Dallas 75390 8852, USA
    Crit Rev Oncol Hematol 62:93-104. 2007
  7. ncbi request reprint Lung cancer in never smokers--a different disease
    Sophie Sun
    Division of Haematology and Oncology and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Nat Rev Cancer 7:778-90. 2007
  8. pmc New molecularly targeted therapies for lung cancer
    Sophie Sun
    Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Clin Invest 117:2740-50. 2007
  9. doi request reprint Clinician Perceptions of Care Difficulty, Quality of Life, and Symptom Reports for Lung Cancer Patients: An Analysis from the Symptom Outcomes and Practice Patterns (SOAPP) Study
    Heidi A Hamann
    Harold C Simmons Cancer Center, Departments of Psychiatry and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts Harold C Simmons Cancer Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas Department of Medical Oncology, Vanderbilt University, Nashville, Tennessee Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois VA New Jersey Health Care System, East Orange, New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey and Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Thorac Oncol 8:1474-83. 2013
  10. doi request reprint Stigma among patients with lung cancer: a patient-reported measurement model
    Heidi A Hamann
    Harold C Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA
    Psychooncology 23:81-92. 2014

Research Grants

  1. NM-404 A Novel Imaging Agent in Lung Cancer
    Joan Schiller; Fiscal Year: 2002
  2. CCNU in NSCLC Patients with Methylation of the MGMT Gene
    Joan Schiller; Fiscal Year: 2003
  3. MID CAREER INVESTIGATOR AWARD
    Joan Schiller; Fiscal Year: 2004
  4. Nano-Structure Surfaces and Liquid Crystal Analysis
    Joan Schiller; Fiscal Year: 2005

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy
    Tien Hoang
    Department of Medicine, University of Wisconsin Medical School, Madison 53792, USA
    Expert Rev Anticancer Ther 2:393-401. 2002
    ..These novel agents target molecular pathways specifically found in cancer cells, thus maximizing the antitumor effect while minimizing toxicities on normal cells...
  2. ncbi request reprint Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
    ..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)...
  3. doi request reprint Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000)
    Joan H Schiller
    University of Texas Southwestern, Dallas, Texas 75390 8852, USA
    Cancer Invest 26:81-95. 2008
    ..Skin rash is the most common toxicity, but is severe (Grade 3) in < 1 percent. This article describes preclinical and clinical development of matuzumab...
  4. doi request reprint Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study
    Joan H Schiller
    University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8852, USA
    J Clin Oncol 27:3836-41. 2009
    ....
  5. pmc Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea
    David E Gerber
    Division of Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    J Clin Oncol 31:1009-20. 2013
    ....
  6. ncbi request reprint Angiogenesis inhibitors in the treatment of lung cancer
    Sophie Sun
    Division of Hematology and Oncology, University of Texas Southwestern, Dallas 75390 8852, USA
    Crit Rev Oncol Hematol 62:93-104. 2007
    ..Recent clinical trials have yielded promising results. This article will review angiogenesis inhibitors targeting the VEGF pathway which are currently being developed for the treatment of lung cancer...
  7. ncbi request reprint Lung cancer in never smokers--a different disease
    Sophie Sun
    Division of Haematology and Oncology and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Nat Rev Cancer 7:778-90. 2007
    ..This Review summarizes our current knowledge of this unique and poorly understood disease...
  8. pmc New molecularly targeted therapies for lung cancer
    Sophie Sun
    Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Clin Invest 117:2740-50. 2007
    ..This article will review the important clinical implications of these advances, with a focus on new molecularly targeted therapies currently in development...
  9. doi request reprint Clinician Perceptions of Care Difficulty, Quality of Life, and Symptom Reports for Lung Cancer Patients: An Analysis from the Symptom Outcomes and Practice Patterns (SOAPP) Study
    Heidi A Hamann
    Harold C Simmons Cancer Center, Departments of Psychiatry and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts Harold C Simmons Cancer Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas Department of Medical Oncology, Vanderbilt University, Nashville, Tennessee Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois VA New Jersey Health Care System, East Orange, New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey and Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Thorac Oncol 8:1474-83. 2013
    ..This study assessed clinicians' perceptions of care difficulty, quality of life (QOL), and symptom reports for their lung cancer patients compared with their patients with breast, prostate, and colon cancer...
  10. doi request reprint Stigma among patients with lung cancer: a patient-reported measurement model
    Heidi A Hamann
    Harold C Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA
    Psychooncology 23:81-92. 2014
    ..This study identified key stigma-related themes to provide a blueprint for item development through a thematic analysis of semi-structured interviews and focus groups with lung cancer patients...
  11. doi request reprint Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer
    Joan H Schiller
    Division of Hematology and Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Texas, USA
    J Thorac Oncol 5:1977-85. 2010
    ....
  12. doi request reprint Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Clin Oncol 26:60-5. 2008
    ..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients...
  13. ncbi request reprint Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis
    Andrea Ardizzoni
    Division of Medical Oncology, University Hospital, Via Gramsci 14, 43100 Parma, Italy
    J Natl Cancer Inst 99:847-57. 2007
    ..Because the efficacy of carboplatin and cisplatin in the treatment of advanced non-small-cell lung cancer (NSCLC) has not been proven to be equivalent, an individual patient data meta-analysis comparing the two treatments was performed...
  14. ncbi request reprint EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer
    Sarita Dubey
    University of California, San Francisco, San Francisco, California 94115, USA
    J Thorac Oncol 1:406-12. 2006
    ..The authors hypothesized that a shorter length of tumor SSR would be associated with poorer survival in patients with non-small cell lung cancer (NSCLC)...
  15. doi request reprint Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study
    Afshin Dowlati
    University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio 44016, USA
    Clin Cancer Res 14:1407-12. 2008
    ....
  16. ncbi request reprint Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...
  17. ncbi request reprint PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2
    Kathy S Albain
    Loyola University, Chicago Medical Center, Maywood, IL 60153, USA
    Clin Lung Cancer 7:417-9. 2006
  18. ncbi request reprint Phase I study of docetaxel and topotecan in patients with advanced malignancies
    Sarita Dubey
    Department of Medicine, Medical Oncology Section, University of Wisconsin Comprehensive Cancer Center, Madison, USA
    J Oncol Pharm Pract 11:131-8. 2005
    ..We designed a phase I study to evaluate the maximum tolerated dose of this combination and to assess the impact of pharmacokinetic interactions of the two drugs on toxicity...
  19. ncbi request reprint Using liquid crystals to report membrane proteins captured by affinity microcontact printing from cell lysates and membrane extracts
    Chang Hyun Jang
    Department of Chemical and Biological Engineering, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Am Chem Soc 127:8912-3. 2005
    ..Detection of epidermal growth factor receptor, a transmembrane glycoprotein, is demonstrated...
  20. ncbi request reprint Small cell lung cancer: defining a role for emerging platinum drugs
    Joan H Schiller
    University of Wisconsin Hospital, Madison, 53792, USA
    Oncology 63:105-14. 2002
    ..If the early promise shown by these compounds is confirmed in the clinic, they may offer a new approach to the treatment of SCLC, including recurrent disease for which limited treatment options are currently available...
  21. ncbi request reprint Novel therapies for lung cancer
    Tien Hoang
    Department of Medicine, Medical Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
    Surg Oncol 11:229-41. 2002
    ....
  22. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors
    James P Thomas
    Department of Medicine, Section of Medical Oncology and University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, 53792, USA
    J Clin Oncol 21:223-31. 2003
    ..A phase I trial of recombinant human endostatin was designed to evaluate toxicity and explore biologic effectiveness in patients with refractory solid tumors...
  23. ncbi request reprint New directions for ZD1839 in the treatment of solid tumors
    Joan H Schiller
    Section of Medical Oncology, Department of Medicine, University of Wisconsin Medical School, Comprehensive Cancer Center, Madison, WI 53792 6164, USA
    Semin Oncol 30:49-55. 2003
    ..Chemoprevention trials have been initiated to assess the potential of ZD1839 to delay or prevent the progression of common solid tumors such as non-small cell lung cancer...
  24. ncbi request reprint Novel therapies for the treatment of non-small cell lung cancer
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Cancer Chemother Biol Response Modif 20:763-86. 2002
    ..In addition, we need new techniques to assist those who are already addicted to escape from tobacco's death grip. Sadly, most users of tobacco still fail to recognize the dangers of their habit. This needs to change!..
  25. ncbi request reprint Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
    Mark G Kris
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY 10021, USA
    JAMA 290:2149-58. 2003
    ....
  26. ncbi request reprint Adjuvant systemic therapies in early-stage non-small-cell lung cancer
    Joan H Schiller
    Medical Oncology, University of Wisconsin Hospital and Clinics, Madison, USA
    Clin Lung Cancer 5:S29-35. 2003
    ..A combination of these new approaches and standard therapy for NSCLC may improve long-term survival in patients with lung cancer..
  27. ncbi request reprint Chemotherapy for advanced non-small cell lung cancer
    Sarita Dubey
    Department of Medicine, University of Wisconsin, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
    Hematol Oncol Clin North Am 18:101-14. 2004
    ..In second-line setting, docetaxel is the agent that has been extensively studied and approved. Furthermore, molecularly targeted therapy holds a promising future and is discussed in articles elsewhere in this issue...
  28. ncbi request reprint Novel agents in the treatment of lung cancer: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 10:4199s-4204s. 2004
  29. ncbi request reprint Clinical trial design issues in the era of targeted therapies
    Joan H Schiller
    University of Wisconsin Madison, Wisconsin, USA
    Clin Cancer Res 10:4281s-4282s. 2004
    ..Although our lack of effective therapies mandates the development of new, molecularly targeted therapies, a number of issues in the design of clinical trials and their end points remain to be considered...
  30. pmc Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients
    David M King
    University of Wisconsin, Madison, WI 53792, USA
    J Clin Oncol 22:4463-73. 2004
    ..To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma...
  31. ncbi request reprint Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial
    David Cella
    Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Ste 100, Evanston, IL 60201, USA
    J Clin Oncol 23:2946-54. 2005
    ..Among these NSCLC patients treated with gefitinib, symptom improvement was complementary to and, for most patients, preceded evidence of radiographic regression...
  32. ncbi request reprint Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab
    Sarita Dubey
    University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA
    Oncologist 10:282-91. 2005
    ..All three drugs are approved for different tumor types, and studies defining their role in NSCLC are under way...
  33. ncbi request reprint Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors
    Diane R Mould
    Projections Research Inc, 535 Springview Lane, Phoenixville, PA 19460, USA
    Clin Pharmacol Ther 71:334-48. 2002
    ..Our objective was to describe the pharmacokinetics and pharmacodynamics of topotecan in patients...

Research Grants6

  1. NM-404 A Novel Imaging Agent in Lung Cancer
    Joan Schiller; Fiscal Year: 2002
    ..The results of this exploratory study will provide the preliminary data for a larger study designed to more accurately estimate the predictive power of NM-404 for staging and/or following response to therapy in NSCLC. ..
  2. CCNU in NSCLC Patients with Methylation of the MGMT Gene
    Joan Schiller; Fiscal Year: 2003
    ..abstract_text> ..
  3. MID CAREER INVESTIGATOR AWARD
    Joan Schiller; Fiscal Year: 2004
    ....
  4. Nano-Structure Surfaces and Liquid Crystal Analysis
    Joan Schiller; Fiscal Year: 2005
    ..abstract_text> ..